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Several CRISPR-Cas9 orthologues have been used for genome editing. Here, we present the
smallest Cas9 orthologue characterized to date, derived from Campylobacter jejuni (CjCas9),
for efﬁcient genome editing in vivo. After determining protospacer-adjacent motif (PAM)
sequences and optimizing single-guide RNA (sgRNA) length, we package the CjCas9 gene,
its sgRNA sequence, and a marker gene in an all-in-one adeno-associated virus (AAV) vector
and produce the resulting virus at a high titer. CjCas9 is highly speciﬁc, cleaving only a limited
number of sites in the human or mouse genome. CjCas9, delivered via AAV, induces targeted
mutations at high frequencies in mouse muscle cells or retinal pigment epithelium (RPE)
cells. Furthermore, CjCas9 targeted to the Vegfa or Hif1a gene in RPE cells reduces the size of
laser-induced choroidal neovascularization, suggesting that in vivo genome editing with
CjCas9 is a new option for the treatment of age-related macular degeneration.
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G
enome editing has recently been democratized by
the development of RNA-guided programmable nucleases
repurposed from the type II clustered regularly
interspaced short palindromic repeats (CRISPR)/CRISPR-
associated (Cas) adaptive immune system against invading
genetic elements in eubacteria and archaea1. Cas9, the single
effector protein component in the system, is complexed with
CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA)
or with single-guide RNA (sgRNA) composed of essential
portions of crRNA and tracrRNA to form a sequence-speciﬁc
RNA-guided endonuclease (RGEN)2. A new RGEN with desired
target speciﬁcity is readily prepared by replacing crRNA
or sgRNA, which hybridizes with a target DNA sequence.
Cas9 RGENs cleave chromosomal DNA in a targeted manner,
enabling genetic modiﬁcations or genome editing in cells and
whole organisms3–8.
Cas9 derived from Streptococcus pyogenes (SpCas9), the ﬁrst
Cas9 orthologue to enable targeted mutagenesis in human
cells3,5,6,9, is still the most widely used among several
Cas9 proteins available for genome editing. Owing to it large
size (1,368 amino acids, 4.10 kbp; Fig. 1a), however, the SpCas9
gene and its sgRNA sequence cannot be packaged together into
certain viral vectors such as adeno-associated virus (AAV)10 for
efﬁcient delivery into cells in vivo. Instead, the SpCas9 gene alone
can be packaged into a single AAV vector in vivo11,12.
Alternatively, SpCas9 can be split into two parts13,14, each can
be packaged into two AAV vectors15,16. However, split SpCas9 is
less active than the intact SpCas9 (refs 13,14). Furthermore, co-
delivery of two AAV vectors is less efﬁcient than the delivery of a
single AAV vector in vivo.
As an alternative to SpCas9, Staphylococcus aureus Cas9
(SaCas9) can be used for genome editing17. SaCas9 is smaller
(1,053 amino acids, 3.16 kbp) than SpCas9 and can be packaged,
together with its sgRNA, into an AAV vector. Still, the SaCas9
gene cannot be packaged with a ﬂorescent reporter gene or two
sgRNAs, essential for targeted chromosomal deletions or other
rearrangements, into a single AAV vector in vivo. Furthermore,
protospacer-adjacent motif (PAM) sequences recognized by
SaCas9, 50-NNGRRT-30, occur less frequently than those
recognized by SpCas9, 50-NGG-30, limiting targetable sites. In
this regard, smaller Cas9 orthologues with different PAM
sequences are highly desired to expand in vivo genome
editing. Here, we present Campylobacter jejuni-derived
Cas9 (CjCas9) for efﬁcient genome editing in vitro and in vivo.
CjCas9 is composed of 984 amino-acid residues (2.95 kbp)
(Supplementary Fig. 1), much smaller than SpCas9 or SaCas9
(Fig. 1a), but has never been shown to induce targeted
mutagenesis in human or other eukaryotic cells or organisms.
In this study, we characterized PAM sequences and optimized the
sgRNA length to utilize CjCas9 for genome editing in mice.
Results
Determination of PAM sequences recognized by CjCas9.
First, we determined the PAM sequences recognized by
CjCas9 in vitro (Fig. 1b). A PCR amplicon library containing
a CjCas9 target sequence followed by randomized 10-base
pair (bp) sequences was cleaved by CjCas9 (and SpCas9 as
a control) and a sgRNA speciﬁc to the target sequence. Cleaved
duplexes were subjected to deep sequencing to identify
PAM sequences recognized by CjCas9. This assay revealed
that CjCas9 recognized 50-NNNNACAC-30 or 50-NNNNRY
AC-30 (where R and Y stands for purines and pyrimidines,
respectively) as PAMs in vitro. Using a different in vitro assay,
Fonfara et al.18 reported that the optimal PAM for CjCas9 was
50-NNNNACA-30.
To conﬁrm the PAM speciﬁcity in human cells, we performed
cell-based reporter assays by co-transfecting plasmids encoding
CjCas9 and its sgRNA and reporter plasmids containing
the target site with variable PAM sequences between RFP and
GFP sequences19 (Fig. 1c). Because the RFP sequence is fused to
the GFP sequence out of frame in these reporter plasmids, cells
express RFP but not GFP (RFPþ GFP ) in the absence
of CjCas9. When CjCas9 cleaves the target site and induces
small insertions or deletions (indels), the GFP sequence can be
fused to the RFP sequence in frame. These reporter assays showed
that CjCas9 cleaved target sites containing 50-NNNNRYAC-30
PAM sequences in HEK 293 cells. Importantly, the cytosine
nucleotide at the 30-end was essential.
Optimization of CjCas9 sgRNA length. We next optimized the
sgRNA length for CjCas9-mediated genome editing in human
and mouse cells (Fig. 2; Supplementary Fig. 2; Supplementary
Table 1). We co-transfected CjCas9 and a series of sgRNAs
with variable lengths into HEK 293 cells or NIH 3T3 cells and
measured indel frequencies using targeted amplicon sequencing.
The ﬁrst nucleotide in the sgRNAs was ﬁxed to an extra guanine
(G) because sgRNAs are transcribed under the control of the
U6 promoter, which requires a guanine at the 50 end. Unlike
SpCas9, which is most active with GX20 sgRNAs that hybridize
with a 20-nucleotide target DNA sequence upstream of a PAM,
CjCas9 was most active with GX22 sgRNAs that hybridize with
a 22 nucleotides target sequence. GX20 and GX19 sgRNAs failed
to induce indels at 8 out of 19 sites and 3 out of 4 sites, respec-
tively in human or mouse cells.
We tested GX22 sgRNAs at 12 sites containing the optimal
50-NNNNACAC-30 PAM in human cells. All of these sgRNAs
co-transfected with CjCas9 were able to induce indels at
frequencies that ranged from 1.0 to 64% (21±5%, on average).
CjCas9 also induced indels at sites with 50-NNNNGCAC-30
PAMs, 50-NNNNGTAC-30 PAMs, and 50-NNNNATAC-30
PAMs albeit less efﬁciently (10±3%, 10±4%, and 16±5%,
respectively).
Genome-wide target speciﬁcities of CjCas9. We then deter-
mined genome-wide speciﬁcities of CjCas9 using nuclease-
digested whole-genome sequencing (WGS; Digenome-seq)20–22.
Cell-free genomic DNA digested with CjCas9 in vitro was
subjected to WGS. Uniform cleavage patterns corresponding to
on-target and off-target cleavage sites were computationally
identiﬁed. CjCas9 designed to target 6 different DNA regions
cleaved between one and 27 sites (7±4 sites, on average) in
the human or mouse genome (Fig. 3a–d). In parallel, we
used Digenome-seq to test three SpCas9 nucleases designed to
cleave sites that overlapped with CjCas9 target sites. SpCas9
cleaved 15 to 147 sites (70±40 sites, on average) in the human or
mouse genome, in line with our previous results showing that
SpCas9 targeted to 11 different sites cleaved 90±30 sites in the
human genome21. One target site in the human genome
contained a 50-NGGNACAC-30 PAM recognized by both
CjCas9 and SpCas9. CjCas9 and SpCas9 cleaved human
genomic DNA at 5 sites and 45 sites, respectively, although the
two Cas9 orthologues showed comparable indel frequencies
at this particular site. Thus, the higher speciﬁcity of CjCas9
was not gained at the expense of its lower editing efﬁciency.
Strikingly, two CjCas9 nucleases targeting the Rosa26 locus
or the Vegfa gene in the mouse genome cleaved genomic
DNA only at the single on-target site, reminiscent of the
remarkable speciﬁcity of Cpf1 nucleases22,23. Sequence logos
obtained computationally by comparing in vitro cleavage sites
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with each other unambiguously showed that these sites contained
50-NNNNACAC-30 or 50-NNNNRYAC-30 PAMs.
We chose the most promiscuous CjCas9 nuclease, which cleaved
genomic DNA at 27 sites, and performed targeted amplicon
sequencing to measure indel frequencies in human cells
(Supplementary Table 2). Indels occurred at the on-target site
but were not detectably induced at the other in vitro cleavage sites.
Taken together, these results show that CjCas9 nucleases are highly
speciﬁc in human cells. The remarkable speciﬁcity of CjCas9 can be
at least partially attributed to its extended, 22 nucleotides target and
4 nucleotides PAM sequences, compared to the 20 nucleotides
target and 2 nucleotides PAM sequences recognized by SpCas9.
Efﬁciency and speciﬁcity of CjCas9. We compared genome
editing efﬁciencies and speciﬁcities of CjCas9 with those of
SaCas9. We chose 3 overlapping sites in the human genome with
50-NNGRRTAC-30 PAM sequences, which can be targeted by
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Figure 1 | CjCas9 and its PAM speciﬁcity. (a) Cas9 orthologues and their sgRNAs. sgRNA structures were obtained using the mfold web server. See also
Supplementary Fig. 1. (b) Schematic showing a PAM assay for characterization of PAM sequences recognized by Cas9. PCR amplicons containing a Cas9
target sequence (yellow) followed by randomized 10-bp (N10) sequences (green) were cleaved by CjCas9 in vitro. The sequence logo showing the
PAM speciﬁcity was obtained using deep-sequencing data. (c) PAM speciﬁcity in cells. Surrogate reporters encoding GFP and RFP and containing a CjCas9
target sequence with degenerate PAMs were transfected with CjCas9 and its sgRNA plasmid into HEK 293 cells. The percentage of cells that express both
GFP and RFP was normalized with that obtained using the optimal reporter containing the 5’-NNNNACAC-3’ PAM sequence. ( ) represents a mock
control. Error bars indicate s.e.m. (n¼ 3).
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Figure 2 | Optimization of sgRNA length for CjCas9. (a) sgRNAs with variable lengths (19 to 23 nucleotide complementary with a target DNA sequence)
were designed and transfected with CjCas9 plasmid into human HEK 293 cells. Genomic DNA was isolated 48 h after transfection. Indel frequencies were
analysed by targeted deep sequencing. The ﬁrst guanine nucleotide at the 5’ end that does not match the target sequence is shown in lower case.
PAM motifs are shown in red. Error bars indicate s.e.m. (n¼ 3). (b) Mutation frequencies at target sites in the mouse genome. Rosa26 and Tp53-speciﬁc
gX22 guide RNAs were designed and transfected into mouse NIH 3T3 cells together with CjCas9 plasmid. Genome editing efﬁciencies were examined by
deep sequencing using genome DNA isolated from cells after 48 h of transfection. PAM motifs are shown in red. Error bars indicate s.e.m. (n¼ 3). See also
Supplementary Fig. 2. (c) CjCas9-mediated genome editing at the human AAVS1 locus with different PAM sequences. sgRNAs targeting sites with
a 5’-NNNNACAC-3’ PAM (green; 12 sgRNAs), 50-NNNNATAC-30 PAM (light blue; 7 sgRNAs), 50-NNNNGCAC-30 PAM (dark blue; 10 sgRNAs), and
50-NNNNGTAC-30 PAM (yellow; 8 sgRNAs) were designed and their activities examined in HEK293 cells with deep sequencing. Error bars indicate
s.e.m. (n¼ 3).
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both CjCas9 and SaCas9. CjCas9 and SaCas9 generated indels at
these sites in HEK 293 cells with comparable frequencies of
35±7% and 36±13%, respectively (Fig. 3e). We then determined
genome-wide speciﬁcities of CjCas9 and SaCas9 nucleases
targeted to two of these overlapping sites using Digenome-seq
(Fig. 3f). CjCas9 and SaCas9 targeted to the AAVS1-TS16 site
cleaved human genomic DNA at 59 and 118 sites, respectively.
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Figure 3 | Genome-wide target speciﬁcities of CjCas9 nucleases examined using Digenome-seq. Human or mouse genomic DNA isolated from HeLa
cells or NIH 3T3 cells (grey), respectively, was digested in vitro by Cas9 and its sgRNA targeted to the human AAVS1 locus (a,b,f) and the mouse Rosa26
(c), Vegfa (c,d) and Hif1a loci (d) and subjected to whole-genome sequencing. Circos plots show genome-wide DNA cleavage scores across the human or
mouse genome. Red arrows indicate on-target sites. N indicates the number of in vitro cleavage sites identiﬁed by Digenome-seq. (a,b) Sequence logos
were obtained by comparing DNA sequences at in vitro cleavage sites with each other. (b) Indel frequencies at the AAVS1-TS8 site measured using targeted
deep sequencing. CjCas9 (orange) or SpCas9 (blue) targeted to the AAVS1-TS8 site was transfected into human HEK293 cells. Error bars indicate
s.e.m. (n¼ 3). (e) Indel frequencies at three AAVS1 sites targeted by CjCas9 (orange) and SaCas9 (violet).
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speciﬁc than were those targeted to the TS16 site, cleaving human
genomic DNA at 2 and 15 sites, respectively. Note that CjCas9
targeted to the TS16 site was more efﬁcient than SaCas9 in terms
of on-target indel frequency (46% versus 28%), suggesting that
the higher speciﬁcity of CjCas9 was not gained at the expense
of a lower on-target efﬁciency. These results demonstrate that
CjCas9 is as efﬁcient as SaCas9 but is more speciﬁc than SaCas9
at least at the sites we tested in human cells.
All-in-one AAV vector for in vivo genome editing. With
its small size, the CjCas9 gene plus a sgRNA sequence can be
packaged into an all-in-one AAV vector (Fig. 4a). CjCas9 directed
to the Rosa26 locus was expressed in C2C12 mouse myotubes
using an AAV serotype DJ (AAVDJ) vector. Indels accumulated
at the target site in a time- and dose-dependent manner
with a frequency of up to 79±7% (Fig. 4b). Because no sites
other than the on-target site were cleaved by this particular
CjCas9 nuclease in the mouse genome, as shown above using
Digenome-seq, we identiﬁed, using Cas-OFFinder24, potential
off-target sites that differed from the on-target site by up to
4 nucleotides in the genome. No indels were detected at the
resulting 20 homologous sites by targeted deep sequencing
even at day 14 post-infection (Supplementary Fig. 3; Suppleme-
ntary Table 3), conﬁrming the high speciﬁcity of this CjCas9
nuclease.
We next packaged the muscle-speciﬁc Spc512 promoter-driven
CjCas9 and the U6 promoter-driven Rosa26-speciﬁc sgRNA into
a muscle-tropic AAV serotype 9 (AAV9) vector25 (Fig. 4c). The
resulting virus was administered via intramuscular injection into
tibialis anterior (TA) muscles of C57BL6J mice (n¼ 3 per group).
CjCas9-induced indels were observed at the target site in
TA muscles with a frequency of 17±1% and 13±2%, 8 weeks
and 32 weeks, respectively, after injection. No indels were
detectably induced at the 20 possible off-target sites in
TA muscles even 32 weeks after injection (Fig. 4d and
Supplementary Table 3), although CjCas9 was still expressed
(Supplementary Fig. 4). This result suggests that a long-term
expression of CjCas9 via AAV in vivo does not necessarily
aggravate off-target effects.
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Figure 4 | AAV-mediated mutagenesis in vitro and in vivo. (a) AAV vector encoding CjCas9 and its sgRNA. (b) Indel frequencies at the Rosa26 target site
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In vivo genome editing in the mouse retina. To show
that CjCas9 can be expressed via AAV in other tissues such as
retina in mice and to investigate the therapeutic potential of
CjCas9-mediated gene surgery for the treatment of age-related
macular degeneration (AMD), a leading cause of blindness in
adults, we prepared an AAV9 vector encoding CjCas9 under the
control of the elongation factor-1 short (EFS) promoter,
enhanced green ﬂuorescent protein (eGFP) linked to the
C terminus of CjCas9 with the self-cleaving T2A peptide, and
a U6 promoter-driven sgRNA speciﬁc to the Vegfa or Hif1a gene,
whose expression in the retina is associated with choroidal
neovascularization (CNV)26,27 (Fig. 5a,b). We monitored the
expression of CjCas9 in the eye and measured indel frequencies
using targeted deep sequencing and VEGFA protein levels
using ELISA, 6 weeks after the resulting viruses were
administered into the eye via intravitreal injection.
In retinal pigment epithelium (RPE) cells, primary target cells
for the treatment of AMD, AAV encoding the Vegfa-speciﬁc
CjCas9 (AAV-CjCas9: Vegfa) achieved indels with frequencies
that ranged from 22 to 30% at day 14, 28, and 42 post injection
(Fig. 5c). As expected, CjCas9-linked eGFP was expressed in
RPE cells (Fig. 5d and Supplementary Fig. 5). At day 42 post
injection, CjCas9-induced indels were observed at Rosa26, Vegfa,
and Hif1a target sites in the retina with a frequency of 44±18%,
20±5, 58±12, respectively (Fig. 5e) and in RPE cells with
a frequency of 14±5%, 22±3%, and 31±2%, respectively
(Fig. 5f). As expected, the VEGFA protein level measured using
ELISA was decreased in the retina treated with AAV encoding the
Vegfa- or Hif1a-speciﬁc CjCas9 (AAV-CjCas9: Vegfa and Hif1a)
but not in those treated with AAV-CjCas9: Rosa26 (Fig. 5g). The
VEGFA protein level was also decreased in RPE cells treated with
the AAV-CjCas9: Vegfa. However, the protein level was not
decreased in those with the AAV-CjCas9: Hif1a or Rosa26
(Fig. 5h), suggesting that VEGFA expression is differentially
regulated in the retina and in RPE cells. We did not measure HIF-
1a protein levels because HIF-1a is degraded under normoxia
conditions. No off-target indels were detectably induced in these
cells at one or two in vitro cleavage sites captured by Digenome-
seq using the Vegfa-speciﬁc or the Hif1a speciﬁc sgRNA,
respectively (Fig. 5i), ruling out the possibility that the partial
suppression of VEGFA expression in the retina and RPE cells
were caused by CjCas9 off-target effects.
Therapeutic genome editing for the treatment of CNV. Next,
we induced CNV in the eye by laser treatment 6 weeks after
injection of AAV and measured the area of CNV 1 week later
(Fig. 6a). Both AAV-CjCas9: Vegfa and AAV-CjCas9: Hif1a
reduced the area of CNV by 24±4% and 20±4%, respectively,
compared to the AAV-uninjected negative control (Fig. 6b–d).
The Rosa26-speciﬁc CjCas9, used as another negative control, did
not show any therapeutic effect. We noted that CjCas9 linked
eGFP was expressed in RPE cells surrounding CNV, which
are a major source of VEGFA in laser-induced CNV (Fig. 6b).
This result shows that the reduction of CNV area coincides with
targeted Vegfa mutagenesis and partial suppression of VEGFA
expression in RPE cells (Fig. 5h).
We then investigated whether the partial gene knockout of
Vegfa and Hif1a in RPE cells using AAV caused any side effect. It
was reported that a conditional knockout of the Vegfa gene but
not that of the Hif1a gene in mouse RPE cells leads to
cone dysfunction28. We measured cone function using full-ﬁeld
electroretinography (ERG) in laser-untreated CNV-free mice
8 weeks after injection of AAV-CjCas9: Vegfa and AAV-CjCas9:
Hif1a (Fig. 6e,f). No signiﬁcant decrease in photopic response
(Fig. 6e) or 30Hz ﬂicker response (Fig. 6f) was observed in these
mice, compared to AAV-uninjected control mice. We also
measured the size of the opsin-positive area, which is closely
related to cone function, in contact with RPE cells expressing
CjCas9. The AAV-CjCas9: Vegfa reduced the size by 30±10%,
compared with the AAV-uninjected control (Fig. 6g,h;
Supplementary Fig. 6), suggesting that the partial Vegfa gene
knockout using AAV can still cause local opsin dysfunction near
Vegfa-edited RPE cells. As expected, however, the AAV-CjCas9:
Rosa26 or AAV-CjCas9: Hif1a did not cause any such cone
dysfunction. Taken together, these results raise a concern
about targeted inactivation of Vegfa in RPE cells using
AAV and suggest that Hif1a could be inactivated without
causing cone dysfunction to avoid neovascularization for the
treatment of AMD.
Discussion
In this report, we have presented a small and highly speciﬁc Cas9
orthologue, derived from C. jejuni, that can be packaged with
a reporter gene in an AAV vector for efﬁcient gene surgery
in vivo. The small size of CjCas9, compared with other
orthologues including Neisseria meningitidis Cas9 (ref. 29),
Streptococcus thermophilus Cas9 (ref. 29), SpCas9 (ref. 30) and
SaCas9 (refs 17,31; Fig. 1a), allows more room for additional
effectors or homology arms required for homologous recombina-
tion in AAV and other animal or plant viral vectors. Because
CjCas9 is highly speciﬁc in vitro and in vivo, we expect that it will
be widely used for precision genome editing in research and gene
surgery in medicine.
In this study, we delivered the CjCas9 gene, its sgRNA
sequence, and the GFP-coding gene to mutate three genes in two
different tissues, TA muscles and eyes, in mice. CjCas9-induced
indels at high frequencies in the Vegfa and Hif1a genes in vivo.
HIF-1a is a hypoxia-inducible transcription factor that activates
the transcription of VEGF A (ref. 32). Unlike VEGF A, a secretory
protein and a primary therapeutic target for the treatment of
AMD, HIF-1a has not been considered as a drug target: Indeed,
HIF1a in particular and transcription factors in general cannot be
targeted directly by antibodies or aptamers or small molecules. In
this study, we showed that CjCas9 targeted to the Hif1a gene in
mouse eyes inactivated the gene in RPE cells efﬁciently and
reduced the area of CNV in a mouse model of AMD. Because
the CjCas9 target site in the mouse Hif1a gene is perfectly
conserved in the human HIF1A gene, the AAV presented in this
study or its variants could be used for the treatment of human
patients in the future. We expect that CjCas9 can be directed to
other traditionally ‘undruggable’ genes or non-coding sequences
to broaden the range of therapeutic targets, making the entire
human genome potentially druggable.
Methods
Animals. The care, use, and treatment of all animals in this study were in strict
agreement with the ARVO statement for the Use of Animals in Ophthalmic and
Vision Research and College of Veterinary Medicine and the guidelines established
by the Seoul National University Institutional Animal Care and Use Committee,
which granted permission to perform animal experiments. Eight-week-old, male,
speciﬁc pathogen-free C57BL/6J mice (n¼ 3–9) were used in this study. Mice were
maintained under a 12 h dark–light cycle.
Laser-induced CNV model. After mice were anaesthetized, pupils were dilated with
an eye drop containing phenylephrine (0.5%) and tropicamide (0.5%). Laser
photocoagulation was performed using an indirect head set delivery system (Iridex)
and laser system (Ilooda). Laser parameters were 810nm wave length, 200mm spot
size, 800mW power and 70ms exposure time. Laser burn was induced three to
four times around the optic disc. Only burns that produced a bubble without vitreous
haemorrhage were included in the study. Seven days later, the eyes were ﬁxed
in 4% paraformaldehyde for 1 h at room temperature. RPE complexes (RPE/choroid/
sclera) were prepared for immunostaining and then incubated with isolectin-B4
(Thermo Fisher Scientiﬁc, cat. no. I21413, 1:100) and anti-GFP antibody
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Figure 5 | In vivo genome editing with CjCas9 in the retina and retinal pigment epithelium. (a) The CjCas9 target sequences in Vegfa and Hif1a/HIF1A
genes. The PAM sequence and the sgRNA target sequence are shown in red and blue, respectively. (b) All-in-one AAV vector encoding CjCas9. (c) Indel
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expression in RPE cells of AAV-CjCas9-injected mice 6 weeks after injection (n¼6). eGFP was stained with anti-GFP antibody (green). Nuclei were
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measured in retina and RPE cells using deep sequencing and ELISA, respectively. (e,f) Indel frequencies at the Rosa26, Vegfa and Hif1a target sites in the
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(g,h) VEGFA levels measured by ELISA in the retina (g) and RPE cells (h), respectively. Error bars indicate s.e.m. (n¼6–7). One-way ANOVA and Tukey’s
post hoc tests, *Po0.05, ***Po0.001. (i) Indel frequencies at in vitro cleavage sites identiﬁed by Digenome-seq. Genomic DNA isolated from RPE cells
treated with AAV-CjCas9 at 6 weeks post injection was subjected to targeted deep sequencing. Mismatched nucleotides are shown in blue and
PAM sequences in red. Red arrows indicate cleavage positions within the 22-bp target sequences.
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(Abcam, ab6556, 1:100) overnight at 4 C. The RPE complex was ﬂat-mounted and
viewed with a ﬂuorescent microscope (Eclipse 90i, Nikon) or a confocal microscope
(LSM 710, Carl Zeiss) at a magniﬁcation of  100. The CNV area was measured
using Image J software (1.47v, NIH) by blinded observers. An average of 3–4 CNV
areas per eye were analysed. Each group consisted of 17–18 eyes.
Construction of cjCas9 and sgRNA plasmids. A human codon-optimized
CjCas9-coding sequence, derived from Campylobacter jejuni subsp. Jejuni NCTC
11168, was synthesized with a nuclear localization signal and an HA epitope at its
C-terminal end (GeneArt Gene Synthesis, Thermo Fisher Scientiﬁc) and cloned
into the p3s plasmid4. The trans-activating crRNA (tracrRNA) sequence and the
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precursor CRISPR RNA (pre-crRNA) sequence were fused with a GAAA or TGAA
linker to form a sgRNA sequence (Supplementary Fig. 1). sgRNAs were transcribed
under the control of the U6 promoter. We used addgene plasmid (# 61591) for
SaCas9 expression.
In vitro PAM identiﬁcation. The recombinant Cas9 protein was expressed in
E. coli and puriﬁed as described previously3. sgRNAs were transcribed using
T7 RNA polymerase as described3. To make a randomized PAM (N10) library, the
DNA sequence including the AAVS1-TS1 target site cloned in a plasmid was
ampliﬁed with a randomized primer. After gel puriﬁcation, the amplicon library
(1mg) was digested with the SpCas9 or CjCas9 protein and in vitro transcribed
sgRNA for 30min at 37 C. Digested library was puriﬁed by column ﬁltration and
subjected to deep sequencing using Miseq (Illumina). Miseq reads that perfectly
matched the reference sequence were sorted. The randomized PAM region was
extracted and analysed with WebLogo.
PAM characterization using cell-based reporter assays. The AAVS1-TS1
target sites with variable PAM sequences, which were randomized at position
X (50-NNNNXCAC-30 , 50-NNNNAXAC-30 , 50-NNNNACXC-30 and 50-NNNN
ACAX-30), were synthesized (Macrogen, Inc.) and cloned in a surrogate reporter
plasmid encoding RFP and GFP19. To determine optimal PAM sequences, each of
the resulting reporter plasmids (100 ng) and plasmids encoding CjCas9 and its
sgRNA (225 and 675 ng, respectively) were co-transfected into HEK293 cells
(1 105) using lipofectamine 2000 (Invitrogen). At day 2 post-transfection, the
fraction of GFP and RFP double-positive cells was determined by ﬂow cytometry
(BD Accuri C6, BD).
Cell culture and mutation analysis. HEK 293 (ATCC, CRL-1573) cells and
mouse NIH 3T3 (ATCC, CRL-1658) cells were maintained in DMEM supple-
mented with 100 units per ml penicillin, 100mgml 1 streptomycin, and 10% fetal
bovine serum (FBS). sgRNA plasmid (750 ng) and CjCas9 plasmid (250 ng) were
transfected into cells (0.5B1 105) with lipofectamine 2000 (Invitrogen). After
48 h of transfection, genomic DNA was isolated using a DNeasy Blood & Tissue kit
(Qiagen) and on-target or off-target loci were ampliﬁed using speciﬁc primers
(Supplementary Table 4) for targeted deep sequencing. Deep-sequencing libraries
were generated by PCR. TruSeq HT Dual Index primers were used to label each
sample. Pooled libraries were subjected to paired-end sequencing (LAS, Inc.). Indel
frequencies were calculated as described previously20.
Digenome sequencing. Digenome-seq was performed as described pre-
viously20,21. Genomic DNA was isolated using a DNeasy Tissue kit (Qiagen)
according to the manufacturer’s instructions. Genomic DNA (8 mg) with CjCas9 or
SaCas9 protein (300 nM) and sgRNA (900 nM) in a 400 ml reaction volume
(100mM NaCl, 50mM Tris-HCl, 10mM MgCl2, and 100mgml 1 BSA) and
incubated the mixture for 8 h at 37 C. Digested genomic DNA was incubated with
RNase A (50 mgml 1) for 30min at 37 C and puriﬁed again with a DNeasy Tissue
kit (Qiagen). Digested DNA was fragmented using the Covaris system and ligated
with adaptors for library formation. DNA libraries were subjected to WGS using an
Illumina HiSeq X Ten Sequencer at Macrogen. We used the Isaac aligner to
generate a Bam ﬁle using the following parameters: ver. 01.14.03.12; Human
genome reference, hg19 from UCSC (original GRCh37 from NCBI, Feb. 2009),
Mouse genome reference, mm10 from UCSC; Base quality cutoff, 15; Keep
duplicate reads, yes; Variable read length support, yes; Realign gaps, no; and
Adaptor clipping, yes (adaptor: 50-AGATCGGAAGAGC*-30, 50-*GCTCTT
CCGATCT-30)33.
AAV vectors encoding CjCas9 and its sgRNA sequences. AAV inverted
terminal repeat-based vector plasmids carrying a sgRNA sequence and the CjCas9
gene with a nuclear localization signal and an HA tag at the C terminus were
constructed. sgRNA transcription was driven by the U6 promoter and CjCas9
expression was controlled by the EFS promoter in C2C12 myoblast cells or by
the Spc512 promoter in TA muscles of C57BL6J mice mice. For retinal delivery, an
AAV vector encoding CjCas9 under the control of the EFS promoter, enhanced
green ﬂuorescent protein (eGFP) linked to the C terminus of CjCas9 with the
self-cleaving T2A peptide, and a U6 promoter-driven sgRNA speciﬁc to the Vegfa
or Hif1a gene was constructed.
Production and characterization of AAV vectors. To produce AAV vectors,
they were pseudotyped in AAVDJ or AAV9 capsids. HEK293T cells were
transfected with pAAV-ITR-CjCas9-sgRNA, pAAVED2/9 and helper plasmid.
HEK293T cells were cultured in DMEM with 2% FBS. Recombinant pseudotyped
AAV vector stocks were generated using PEI coprecipitation with PEIpro
(Polyplus-transfection) and triple-transfection with plasmids at a molar ratio of
1:1:1 in HEK293T cells. After 72 h of incubation, cells were lysed and particles were
puriﬁed by iodixanol (Sigma-Aldrich) step-gradient ultracentrifugation. The
number of vector genomes was determined by quantitative PCR.
AAV transduction in mouse myoblast cells. Mouse myoblast cells were
infected with AAVDJ-CjCas9 at different viral doses (multiplicity of infection
(MOI): 1, 5, 10, 50, and 100 determined by quantitative PCR) and maintained
in DMEM with 2% FBS. At different time points, cells were collected for targeted
deep sequencing. An MOI of 1 was estimated with one infectious virus particle
in 100 total viral particles determined by quantitative PCR.
Intramuscular injection of AAV. AAV was administered to 8-week-old young
adult male C57BL/6J mice anaesthetized with 2–4% isoﬂurane. The mice were
injected intramuscularly with AAV9-CjCas9 (1 1011 viral genome) in physiolo-
gical saline (40 ml) using an ultra-ﬁne insulin syringe with a 31G needle (BD).
As a negative control, C57BL/6J mice were injected with physiological saline
(40 ml) only.
Intravitreal injection of AAV. 8-week-old mice were anaesthetized with an
intraperitoneal injection of a mixture of tiletamine and zolazepam (1:1, 2.25mg per
kg body weight) and xylazine hydrochloride (0.7mg per kg body weight).
AAV9-CjCas9 (2 1010 viral genome in 2 ml) was intravitreally injected using
a Nanoﬁl syringe with a 33G blunt needle (World Precision Instruments Inc.)
under an operating microscope (Leica Microsystems Ltd.).
Immunoﬂuorescent staining and imaging of retinal tissue. For the analysis of
opsin-positive area, formalin-ﬁxed parafﬁn-embedded samples were prepared at
day 42 post injection (n¼ 4). Cross-section samples were immunostained with
anti-HA antibody (Roche, 3F10, 1:1,000), anti-opsin antibody (Millipore, AB5405,
1:1,000), and Alexa Fluor 488 or 594 antibodies (Thermo Fisher Scientiﬁc, 1:500).
The opsin-positive area corresponding to RPE cells expressing HA-tagged CjCas9
was measured using Image J software (1.47v, NIH) by blinded observers. For the
distribution of CjCas9 and eGFP, the eyes were ﬁxed in 4% paraformaldehyde for
1 h at room temperature. RPE complexes (RPE/choroid/sclera) were prepared for
immunostaining and then incubated with anti-GFP antibody (Abcam, ab6556,
1:100) overnight at 4 C. After stain with Alexa Fluor 488 antibodies (1:500), the
RPE ﬂat-mounts was imaged using a confocal microscope (LSM 710, Carl Zeiss).
The scanning parameters were as follows: scaling (x¼ 0.042 mm per pixel,
y¼ 0.042mm per pixel, z¼ 0.603 mm per pixel), dimensions (x¼ 1,024, y¼ 1,024,
channels: 2, 8-bit) with objective C-Apochromat  40 per 1.20W Korr M27.
ZEN 2 software was used to process the images.
Figure 6 | CjCas9 targeted to Vegfa or Hif1a reduces the area of laser-induced CNV in mice. (a) At day 42 post injection of AAV-CjCas9, mice was
treated with laser to induce choroidal neovascularization (CNV). One week after laser treatment, the CNVarea was analysed. (b) In vivo expression of eGFP
coexpressed with CjCas9 in laser-induced CNV. Representative confocal images of eGFP expression in the RPE of laser-induced CNV, 6 weeks after
injection of AAV-CjCas9: Hif1a. eGFP was stained with anti-GFP antibody (green), CNV was stained with anti-IB4 antibody (red), and nuclei were counter-
stained with DAPI (blue). Scale bar, 200 mm. Arrows indicate eGFP-expressing RPE cells. Scale bar, 100mm (enlarged image). (c) Representative laser-
induced CNV stained with isolectin B4 in the mouse eye injected with AAV-CjCas9 targeted to Rosa26, Vegfa or Hif1a. Scale bar, 200mm. (d) The CNVarea.
Error bars indicate s.e.m. (n¼ 17–18). One-way ANOVA and Tukey’s post hoc tests, *Po0.05; **Po0.01; ***Po0.001; NS, not signiﬁcant. (e,f) At day 56
post AAV injection, full-ﬁeld electroretinogram (ERG) was performed to evaluate cone function in mice. There was no signiﬁcant decrease of b-wave of
photopic response (e) and 30Hz ﬂicker response (f) in both AAV-CjCas9: Vegfa (n¼8) or AAV-CjCas9: Hif1a (n¼ 6) treated mice, compared to normal
control mice (n¼8). Error bars indicate s.e.m. (n¼6–8). (g,h) Opsin-positive areas in the retina at day 42 post injection. (g) Representative images of
opsin-positive areas in contact with RPE cells expressing HA-tagged CjCas9 in AAV-CjCas9: Rosa26, Vegfa or Hif1a injected mice compared with the
AAV-uninjected negative control mice (no AAV). Opsin (red) and DAPI (blue). Scale bar, 20mm. ONL, outer nuclear layer; IS, inner segment of
photoreceptor cells; OS, outer segment of photoreceptor cells. See also Supplementary Fig. 6. (h) Relative opsin areas of the AAV-CjCas9-injected mice
were normalized to that of the AAV-uninjected negative control mice. Error bars indicate s.e.m. (n¼4). One-way ANOVA and Tukey’s post hoc tests,
*Po0.05.
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Genomic DNA extraction. For DNA extraction from muscle, muscle tissue was
homogenized using tungsten carbide beads (3mm; Qiagen) and a TissueLyser II
(Qiagen). For extraction from RPE, after imaging of RPE ﬂat-mounts, tissue
samples were washed in PBS. RPE cells were mechanically isolated from choroid/
sclera by vortexing for 30 s in lysis buffer (NucleoSpin Tissue, Macherey-Nagel), as
described34. Genomic DNA from the remnant choroid/sclera tissues was analysed
to conﬁrm complete isolation of RPE cells. Genomic DNA was analysed by targeted
deep sequencing.
Mouse Vegfa ELISA. At day 42 post injection, whole RPE complexes were
separated from neural retina tissue and frozen for further analysis. Sample
tissues were lysed with Cell Lysis Buffer (120 ml) (CST #9803) and Vegfa
protein levels were measured using a mouse VEGF Quantikine ELISA kit
(MMV00, R&D systems) according to the manufacturer’s instructions.
ERG analysis. Mice were dark-adapted over 16 h. Mice were anaesthetized with an
intraperitoneal injection of a mixture of tiletamine and zolazepam (1:1, 2.25mg per
kg body weight) and xylazine hydrochloride (0.7mg per kg body weight). Pupils
were dilated with an eye drop containing phenylephrine (0.5%) and tropicamide
(0.5%). Contact lens electrodes were placed on both eyes with a drop of methyl-
cellose. Full-ﬁeld ERGs were recorded as described35 by using the universal
testing and electrophysiologic system 2000 (UTAS E-2000, LKC Technologies,
Gaithersburg, MD). The responses were recorded at a gain of 2 k using a notch
ﬁlter at 60Hz, and were bandpass ﬁltered between 0.1 and 1,500Hz. In the
light-adapted state (photopic), with a 30 cd/m2 background light to desensitize
the rods and isolate cones, cone responses were recorded in response to single
ﬂashed of 0 dB for photopic response, and a ﬂicker sequence of 30Hz, averaging
20 responses. The amplitude of the a-wave was measured from the baseline to the
lowest negative-going voltage, whereas peak b-wave amplitudes were measured
from the trough of the a-wave to the highest peak of the positive b-wave.
Western blotting. The CjCas9 protein expressed in TA muscles of C57BL/6J mice
at 8 months after injection of AAV was detected using western blotting. Samples
containing equal amounts of protein (20 mg) were analysed; Cas9 and GAPDH
were detected with an anti-HA high afﬁnity antibody (Abcam, ab9110, 1:5,000) and
an anti-GAPDH antibody (Abcam, ab9485, 1:2,500), respectively. Goat anti-rabbit
IgG-HRP antibody (Abcam, ab6721, 1:5,000) was used for signal detection.
ImageQuant LAS4000 (GE healthcare) was used for digital imaging. Uncropped
scans of blots in main ﬁgures are presented in Supplementary Fig. 4.
Statistical analysis. No statistical methods were used to predetermine sample size
for in vitro or in vivo experiments. All group results are expressed as mean±s.e.m.,
if not stated otherwise. Comparisons between groups were made using the two-
tailed Student’s t-test or one-way analysis of variance (ANOVA) and Tukey’s
post hoc tests for multiple groups. Statistical signiﬁcance as compared with
untreated controls was denoted with *Po0.05, **Po0.01, ***Po0.001 in the
ﬁgures and ﬁgure legends. Statistical analysis was performed in Graph Pad
PRISM 5.
Data availability. The deep-sequencing data from this study have been submitted
to the NCBI Sequence Read Archive under accession number SRP095501 and
SRP095507. The data that support the ﬁndings of this study are available from the
corresponding author upon reasonable request.
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